Drug Profile
Research programme: viral infections and cancer VLP vaccines - TechnoVax
Alternative Names: Cancer vaccine - TechnoVax; Dengue vaccine - TechnoVax; HIV vaccine - TechnoVax; Inhaled powder influenza VLP vaccine - TechnoVax; Inhaled powder RSV VLP vaccine - TechnoVax; Pandemic influenza vaccine - TechnoVax; Respiratory syncytial virus (RSV) VLP vaccine - TechnoVax; Seasonal tetravalent influenza VLP vaccine - TechnoVax; Universal influenza vaccine - TechnoVax; Virus-like particle (VLP) vaccines - TechnoVax; Zika virus vaccine - TechnoVax; ZIKA VLP vaccine - TechnoVaxLatest Information Update: 28 Jun 2021
Price :
$50
*
At a glance
- Originator TechnoVax
- Developer City University of New York; TechnoVax
- Class AIDS vaccines; Cancer vaccines; Dengue vaccines; Influenza A vaccines; Influenza virus vaccines; Virus-like particle vaccines; Zika virus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer; Dengue; HIV infections; Influenza virus infections; Parainfluenza virus infections; Respiratory syncytial virus infections; Zika virus infection
Most Recent Events
- 28 Jun 2021 No recent reports of development identified for preclinical development in Zika-virus-infection in USA (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Dengue in USA (Parenteral)